Anti Inflammatory News and Research

RSS

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Trans fats raises stroke risk in women – aspirin lowers risk

A new study finds that older women who take in substantial amount of trans fats are more likely than their counterparts to suffer an ischemic stroke. However, the risk of stroke associated with trans fat intake was lower among women taking aspirin, according to the findings from University of North Carolina at Chapel Hill researchers. The report, “Trans Fat Intake, Aspirin and Ischemic Stroke Among Postmenopausal Women,” was published today online in the journal Annals of Neurology.

2 Mar 2012

Akeso Medical Imaging starts clinical study for proof of concept of imaging device for rheumatoid arthritis disease activity monitoring and control

Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso’s imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.

1 Mar 2012

Aspirin may reduce risk of trans fat-related stroke in older women

Older women whose diets include a substantial amount of trans fats are more likely than their counterparts to suffer an ischemic stroke, a new study shows.

1 Mar 2012

New NOSH-aspirin appears more effective against cancer

Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.

29 Feb 2012

Walnuts associated with better memory scores and cognitive function

Do you recall what you ate for breakfast today or dinner last night? According to new research, you may have a better chance of remembering if you include walnuts. Recent findings published in the Journal of Alzheimer's Disease report walnut consumption in a Mediterranean diet is associated with better memory scores and cognitive function.

29 Feb 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

Citrus fruits may keep stroke at bay for women

In the study published last Thursday in Stroke, a journal of the American Heart Association, researchers analyzed the flavonoid intake of 69,622 women from the U.S.-based Nurses’ Health Study, which has followed nurses since 1976 to assess risk factors for cardiovascular disease and cancer. The total flavonoid intake of the 69,622 women was calculated after they completed food intake questionnaires collected every four years using a U.S. Department of Agriculture database. They found that during 14 years of follow up surveys beginning in 1990, 1,803 incidents of strokes were confirmed from the women.

26 Feb 2012

EMA accepts MAA filing of Genzyme's teriflunomide for MS

Genzyme, a Sanofi company, announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS).

24 Feb 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012

Pharmacist-led interventions can help reduce medication errors in primary care

Medication errors are common in primary care but the number of mistakes could be reduced significantly if GPs introduced an in-house pharmacist-led intervention scheme.

21 Feb 2012

Low dose carbon monoxide therapy can prevent fetal death

Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.

19 Feb 2012

The 'nutritional magic' behind soy's heart health benefits

Nutrition science has regarded soy as a superfood with many health benefits for decades. In fact, "25 grams of soy protein per day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease," according to the FDA.

18 Feb 2012

New group of compounds may protect brain cells from inflammation

Scientists at Emory University School of Medicine have identified a new group of compounds that may protect brain cells from inflammation linked to seizures and neurodegenerative diseases.

15 Feb 2012

Aspirin-like drugs help prevent spread of tumors in the body

Australian scientists have made a breakthrough which could help in the fight against cancer. The team from Peter MacCallum Cancer Centre in Melbourne has found a link between non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and the ability of tumours to spread in the body. They say that doctors have been aware of the benefits of NSAIDs for many years, but did not fully understand the biological processes involved.

14 Feb 2012

Scientists identify more than 100 new cases of alkaptonuria

Scientists at the University of Liverpool, working with international partners, have shown a rare genetic disease, that causes crippling osteoarthritis in the spine and major joints, is far more prevalent worldwide than previously thought.

14 Feb 2012

Santarus initiates enrollment in UCERIS Phase IIIb study for ulcerative colitis

Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.

13 Feb 2012

Cyanotech third quarter revenues increase to $6,706,000

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the third quarter and first nine months of fiscal year 2012, ended December 31, 2011.

9 Feb 2012

Tailoring TB treatment based on a patient's genetic sequence

A gene that influences the inflammatory response to infection may also predict the effectiveness of drug treatment for a deadly form of tuberculosis.

8 Feb 2012

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Anacor Pharmaceuticals announced today that its partner GlaxoSmithKline has voluntarily paused enrollment in its current clinical trials of GSK2251052 due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

6 Feb 2012